Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design

Copyright © 2018. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 195(2018) vom: 05. Okt., Seite 28-35
1. Verfasser: Jackson, Doreen O (VerfasserIn)
Weitere Verfasser: Trappey, Francois A, Clifton, G Travis, Vreeland, Timothy J, Peace, Kaitlin M, Hale, Diane F, Litton, Jennifer K, Murray, James L, Perez, Sonia A, Papamichail, Michael, Mittendorf, Elizabeth A, Peoples, George E
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase II Journal Article Randomized Controlled Trial Breast Cancer HER2 expression HLA-status Immunotherapy Cancer Vaccines HLA-A2 Antigen Vaccines, Subunit mehr... Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1 ERBB2 protein, human EC 2.7.10.1 Receptor, ErbB-2